甲状腺がん診断市場レポート：2030年までの動向、予測、競合分析

甲状腺がん診断の動向と予測

世界の甲状腺がん診断市場の将来は、病院、関連研究所、独立診断研究所、画像診断センター、がん研究所の各市場における機会によって有望視されています。世界の甲状腺がん診断市場は、2024年から2030年までのCAGRが5.5%で、2030年までに推定76億米ドルに達すると予想されます。この市場の主な促進要因は、甲状腺がんの罹患率の増加、リアルタイムの診断と治療への注目の高まり、甲状腺がんに対する意識の高まりです。

• Lucintelの予測では、検査タイプ別では、高解像度でリアルタイムの画像検査に対する需要の増加により、画像検査が引き続き最大セグメントとなります。
• エンドユースカテゴリーでは、病院におけるがん診断患者の増加、消費者の意識の高まり、世界のヘルスケアインフラへの投資の増加により、病院が予測期間中最大のセグメントであり続けると思われます。
• 地域別では、甲状腺がんの有病率の増加、医療費の増加、米国における意識向上、診断、治療に対する政府の積極的な取り組みにより、北米が最大地域であり続けると思われます。

甲状腺がん診断市場の戦略的成長機会

甲状腺がん診断市場は、さまざまな用途で急速な成長を遂げています。これらの機会は、技術開発、ヘルスケア支出の増加、患者ケアの改善から生じています。

• 新しいAI対応診断ツールの開発：最新の診断ツールのAI強化機能により、成長の見込みが生まれます。AIアルゴリズムは多数の画像を読み取り、微細な特徴を検出して結論をより正確にすることができます。AIソリューションの出現は、筋障害の診断の質とスピードを高め、市場成長に寄与します。
• 非侵襲的な新しい診断方法：血液生検や画像診断などの高度な技術が医療分野で普及しています。これらの非侵襲的な方法は、診断をより便利にし、患者の苦痛を軽減します。この動向は市場の大きな成長機会となります。
• 分子診断アプリケーションの増加：遺伝学的検査やゲノム検査などの分子診断の採用が増加する傾向が現れており、これはより多くの収益を生むであろう。これらの技術は甲状腺がんの生物学的側面を解明し、治療アプローチを導き、診断精度を高める。
• 既存の早期発見プログラムの強化：甲状腺がんの早期発見プログラムの確立が注目されています。このようなプログラムは、病気の早期発見を容易にすることで治療費を下げることができるため、有益です。早期発見プログラムには成長の可能性があります。
• 新市場の開拓：アジアとラテンアメリカの新興市場は、ヘルスケアの受け入れが進み、甲状腺がんに対する認識が高まっているため、成長機会を提供すると思われます。診断能力の拡大は、早期診断と治療へのアクセスを増加させることで市場の成長につながると期待されます。

これらの戦略的成長機会を活用することで、次世代の甲状腺がん診断市場が創出され、診断の質が向上し、患者へのアクセシビリティが高まり、市場成長が促進されます。これらの機会を活用することで、甲状腺がんの診断と治療がさらに向上します。

甲状腺がん診断市場の促進要因・課題

甲状腺がん診断市場は、その成長と開拓に影響を与えるいくつかの促進要因・課題の影響を受けています。これらの要因には、市場構造を形成する技術的変化、市場経済、規制政策などが含まれます。

甲状腺がん診断市場を牽引する要因は以下の通り：

• 技術の進歩：画像診断、AI、分子診断の新デバイスが市場を前進させる。これらの技術は、診断と介入がより効果的かつ迅速に行われることを保証し、患者の転帰を改善し、市場成長に寄与します。
• ヘルスケア投資の増加：ヘルスケアのインフラストラクチャーや研究に対する資金が増加し、診断機器の改良が促進されています。投資の増加は、甲状腺がん診断業界における新たな技術開発を取り込むことで生産性を高める。
• スクリーニングプログラムに対する認識と普及率の高まり：甲状腺がんに対する感度が向上し、正確な一般検診プログラムが実施されています。この意識は市場成長にプラスの影響を与えます。
• 甲状腺がん患者の増加：世界の甲状腺がん患者の増加により、診断サービスへの需要が高まっています。治療を受けるために新しい診断法を求める患者が増加しています。
• 標的療法の採用増加：個別化医療、特に標的療法と個別化診断法へのシフトが成長を促進しています。このような進歩は、患者の福祉を高め、市場力学を変化させる新しい方法の設計に役立ちます。

甲状腺がん診断市場における課題は以下の通り：

• 高価な高度診断検査：高度な診断検査は高価です。高度な画像診断機器にかかる費用は、より簡便な手技に比べ高いため、貧しい地域での入手や使用の妨げとなっています。このコストの問題は、診断サービスの発展と公平な提供を妨げます。
• 規制上の制約：複雑な規制のため、新しい診断機器の承認取得にはコストと時間がかかります。このような障害は、コンプライアンス・タイムラインや経済的側面に影響を及ぼす可能性があります。
• 農村部における医療サービスの限られた利用可能性：農村部や医療サービスが行き届いていない地域での診断サービスへのアクセスは依然として限られています。これらの地域で診断ツールを利用しやすく安価にすることは、市場の成長とヘルスケア提供システムの強化にとって極めて重要です。

甲状腺がん診断市場の成長は、技術の進歩、資金調達の増加、病気に対する意識の高まりなどの要因によって形成されます。しかし、高コスト、規制上の問題、アクセス制限などの課題は依然として解決されておらず、効果的な診断と治療に対する市場の可能性を制限しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の甲状腺がん診断市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の甲状腺がん診断市場の動向（2018～2023年）と予測（2024～2030年）
• 世界の甲状腺がん診断市場、製品タイプ別
  • 機器
  • 消耗品とアクセサリー
• 世界の甲状腺がん診断市場、検査タイプ別
  • 画像検査
  • 生検
  • 血液検査
  • その他
• 世界の甲状腺がん診断市場、最終用途別
  • 病院
  • 関連ラボ
  • 独立診断研究所
  • 画像診断センター
  • がん調査機関
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別の世界の甲状腺がん診断市場
• 北米の甲状腺がん診断市場
• 欧州の甲状腺がん診断市場
• アジア太平洋の甲状腺がん診断市場
• その他地域の甲状腺がん診断市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 製品タイプ別の世界の甲状腺がん診断市場の成長機会
  • 検査タイプ別の世界の甲状腺がん診断市場の成長機会
  • 世界の甲状腺がん診断市場における最終用途別の成長機会
  • 地域別の世界の甲状腺がん診断市場の成長機会
• 世界の甲状腺がん診断市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の甲状腺がん診断市場の能力拡大
  • 世界の甲状腺がん診断市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Abbott
• Hoffmann-La Roche
• Thermo Fisher Scientific
• Siemens Healthcare
• Bio-Rad Laboratories
• General Electric
• Koninklijke Philips
• Toshiba Corporation
• Agilent Technologies
• Illumina

Thyroid Cancer Diagnostic Trends and Forecast

The future of the global thyroid cancer diagnostic market looks promising with opportunities in the hospital, associated lab, independent diagnostic laboratory, diagnostic imaging center, and cancer research institute markets. The global thyroid cancer diagnostic market is expected to reach an estimated $7.6 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are the increasing incidence of thyroid cancer, the growing focus on real-time diagnosis and treatment, and rising awareness of thyroid cancer.

• Lucintel forecasts that, within the test type category, imaging testing will remain the largest segment due to the increasing demand for high-resolution and real-time image testing.
• Within the end-use category, hospitals will remain the largest segment over the forecast period due to the growing inflow of cancer diagnosis patients in hospitals, increasing consumer awareness, and growing investments in healthcare infrastructure across the globe.
• In terms of regions, North America will remain the largest region due to the increasing prevalence of thyroid cancer, rising healthcare expenditure, and favorable government initiatives in the US for awareness, diagnosis, and treatment.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic industry is quickly adapting to emerging trends. These trends result from technological advancements, enriched research, and transformations in social behavior, which foster new avenues for improved service and patient care.

• Enabling Sound Commitments in Diagnostics Using AI: The application spectrum of AI, machine learning, and imaging technologies in the detection and risk prediction of cancer is constantly widening. For instance, the patterns that enhance the prediction of thyroid cancer detection using AI algorithms are often overlooked by human readers. This trend helps achieve better and earlier SARs, thereby lowering health risks for patients.
• Enhancement of Liquid Biopsy Potentials: Liquid biopsy is emerging as a viable, non-invasive method to identify cancer-causing markers in the blood. This technology can detect the presence and progression of thyroid cancer without requiring a tissue biopsy. It significantly improves the quality of personalized medicine.
• Formation of Molecular Diagnostics with Genetic Testing: Molecular diagnostics and genetic testing provide further insights into thyroid cancer at the molecular level. This includes advanced techniques such as next-generation sequencing (NGS), which enable the detection of mutations and other biomarkers linked to thyroid cancer for personalized therapy and diagnostics.
• Using Advanced Imaging Techniques: The development of imaging technologies, including high-frequency ultrasound and sophisticated MRI, bolsters the ability to identify and classify thyroid nodules and cancer. These technologies offer higher resolution and precision, leading to earlier and more accurate diagnoses, which are essential for patient treatment.
• Patient-Focused Diagnostics: There is an increasing emphasis on incorporating patient-centered diagnostic methods designed to cater to population needs and specific clinical instances. This trend aims to compile information on patients' desires and medical history to create unique diagnostic and therapeutic approaches focused on the individual, enhancing patient experience and outcomes.

These trends are transforming the thyroid cancer diagnostic market by increasing accuracy, facilitating early diagnosis, and integrating patient care services. They represent significant steps forward that will enhance the feasibility of developing new diagnostic modalities with safer and more effective therapeutics, benefiting patient well-being and reducing healthcare costs.

Recent Developments in the Thyroid Cancer Diagnostic Market

Recent achievements in the thyroid cancer diagnostic market reflect significant sophistication and growth in technology and methodology. This evolution is supported by studies, technological innovations, and investments in healthcare that improve direct patient care and assist in managing thyroid disease.

• Precision Medicine Approaches: In recent years, precision medicine has evolved into a paradigm for determining the most appropriate diagnostics for thyroid cancer imaging based on the patient's unique genetic and molecular characteristics. This approach allows for greater precision in accurate diagnoses and effective therapeutic interventions, enhancing patient care and minimizing treatment resource waste.
• Advanced Imaging Technologies: The implementation of new technologies, including high-frequency rescue ultrasound and molecular imaging studies, contributes to better thyroid nodule detection and characterization. These technologies provide high-quality images and information, thus enhancing sensitivity and increasing positive predictive value.
• AI and Machine Learning Integration: Improved imaging techniques enable the use of artificial intelligence and machine learning in imaging processes, enhancing image analysis and detecting both subtle and conspicuous features suggesting thyroid cancer. These technologies increase the likelihood of relevant findings and improve the reliability of positive diagnoses.
• Liquid Biopsy Innovations: Liquid biopsy techniques are being refined to provide more accurate detection of thyroid cancer-associated markers in blood samples. This less invasive procedure is preferable and more effective than conventional tissue biopsies for earlier diagnosis and disease follow-up.
• Advances in Molecular Diagnostics: Technological innovations for molecular diagnostics, especially revolutionary next-generation sequencing, have enabled more detailed analyses of the genetic and molecular features of thyroid cancers. These developments provide clearer diagnoses and efficient treatment procedures, improving the services received by patients.

These advancements are reshaping the thyroid cancer diagnostic market by increasing diagnostic accuracy, enabling early cancer detection, and providing tailored therapies to affected individuals. Such advancements are crucial for enhancing condition management and patient welfare.

Strategic Growth Opportunities for Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic market is experiencing rapid growth across various applications. These opportunities stem from technological developments, increased healthcare expenditure, and improvements in patient care.

• Development of New AI-Enabled Diagnostic Tools: The AI-enhanced capabilities of modern diagnostic tools create growth prospects. AI algorithms can read numerous images, detecting minute features and making conclusions more precise. The emergence of AI solutions enhances the quality and speed of diagnosing muscle disorders, contributing to market growth.
• New Non-Invasive Ways to Diagnose: Advanced techniques, including blood biopsies and imaging, are gaining traction in the medical field. These non-invasive methods make diagnosis more convenient and less distressing for patients. This trend represents a significant growth opportunity in the market.
• Increase in the Application of Molecular Diagnostics: There is an emerging trend toward increased adoption of molecular diagnostics, such as genetic and genomic testing, which will generate more revenue. These technologies elucidate the biological aspects of thyroid cancer, guiding treatment approaches and enhancing diagnostic accuracy.
• Enhancement of Existing Early Detection Programs: Attention is being directed toward instituting early detection programs for thyroid cancer. Such programs are advantageous, as they can lower therapeutic expenses by facilitating earlier disease detection. There is potential for growth in early detection initiatives.
• Opening Up to New Markets: Emerging markets in Asia and Latin America are likely to provide growth opportunities due to increasing healthcare acceptance and rising awareness of thyroid cancer. Expanding diagnostic capabilities is expected to lead to market growth by increasing access to early diagnosis and treatment.

Leveraging these strategic growth opportunities will help create the next generation of the thyroid cancer diagnostic market, enhancing diagnostic quality, increasing patient accessibility, and promoting market growth. Utilizing these opportunities will further improve the diagnosis and treatment of thyroid cancer.

Thyroid Cancer Diagnostic Market Driver and Challenges

The market for thyroid cancer diagnosis is influenced by several drivers and challenges that affect its growth and development. These factors include technological changes, market economics, and regulatory policies that shape the market structure.

Factors driving the thyroid cancer diagnostic market include:

• Technological Advancements: New devices in imaging, AI, and molecular diagnostics propel the market forward. These technologies ensure that diagnoses and interventions are conducted more effectively and quickly, improving patient outcomes and contributing to market growth.
• Increasing Healthcare Investments: More funding for healthcare infrastructure and research is facilitating the improvement of diagnostic equipment. Increased investment enhances productivity by embracing new technological developments in the thyroid cancer diagnostic industry.
• Growing Awareness and Prevalence of Screening Programs: There is improved sensitivity to thyroid cancer and the implementation of accurate general screening programs. This awareness positively affects market growth.
• Increase in Thyroid Cancer Cases: The rising number of thyroid cancer patients worldwide increases the demand for diagnostic services. More patients seek new diagnostic procedures to receive treatment.
• Increasing Adoption of Targeted Therapies: The shift toward personalized medicine, especially targeted therapies and tailored diagnostic methods, is driving growth. Such advancements help design new methods that enhance patient welfare and change market dynamics.

Challenges in the thyroid cancer diagnostic market include:

• Expensive Advanced Diagnostic Tests: High costs associated with sophisticated imaging instruments, compared to simpler procedures, hinder availability and use in poorer regions. This cost issue hampers the development and equitable provision of diagnostic services.
• Regulatory Constraints: Obtaining regulatory approvals for new diagnostic devices is costly and time-consuming due to complex regulations. These impediments can affect compliance timelines and economic aspects.
• Limited Availability of Health Services in Rural Areas: Access to diagnostic services in rural and underserved areas remains limited. Making diagnostic tools accessible and affordable in these regions is crucial for market growth and enhancing healthcare delivery systems.

Factors such as technological progress, increased funding, and heightened awareness about diseases shape the growth of the thyroid cancer diagnostic market. However, challenges such as high costs, regulatory issues, and limited accessibility remain unaddressed, limiting the market's potential for effective diagnosis and treatment.

List of Thyroid Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies thyroid cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the thyroid cancer diagnostic companies profiled in this report include-

• Abbott
• Hoffmann-La Roche
• Thermo Fisher Scientific
• Siemens Healthcare
• Bio-Rad Laboratories
• General Electric
• Koninklijke Philips
• Toshiba Corporation
• Agilent Technologies
• Illumina

Thyroid Cancer Diagnostic by Segment

The study includes a forecast for the global thyroid cancer diagnostic by product type, test type, end use, and region.

Thyroid Cancer Diagnostic Market by Product Type [Analysis by Value from 2018 to 2030]:

• Instruments
• Consumables & Accessories

Thyroid Cancer Diagnostic Market by Test Type [Analysis by Value from 2018 to 2030]:

• Imaging Test
• Biopsy
• Blood Test
• Others

Thyroid Cancer Diagnostic Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital
• Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Thyroid Cancer Diagnostic Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic market is dynamically evolving due to technological development, growing awareness, and increased funding for research. The United States, China, Germany, India, and Japan are at the forefront of this evolution, providing novel diagnostic approaches and better healthcare systems. These developments are transforming thyroid cancer detection, improving effectiveness, and enabling earlier detection.

• United States Progress: The U.S. is advancing in precision medicine and liquid biopsy. Research-oriented tests for genetic and molecular screening are being developed, resulting in more efficient early diagnostic markers and treatment modalities. This bidirectional technology transfer is further enhanced by the FDA's fast-tracking of new diagnostic devices.
• China: By expanding investment in research and development, China aims to broaden its diagnostic capabilities. Recent developments include the use of AI in imaging and diagnostics to assist in early thyroid cancer detection, with a focus on enhancing services for underserved rural populations.
• Germany: Germany is at the forefront of applying emerging imaging techniques, such as super-resolution ultrasound and molecular imaging for patients. The country is also making strides in searching for additional biomarkers and non-invasive techniques, aimed at improving diagnostic quality and outcomes.
• India: In India, initiatives are underway to enhance access to affordable diagnostic services and products. Innovations include low-cost molecular assays and new imaging technologies, alongside efforts to train healthcare providers for more accurate diagnoses and better services in underserved areas.
• Japan: Japan is advancing the development of new diagnostic modalities, particularly next-generation molecular diagnostics and imaging. The country is also enhancing existing early detection programs, expanding public health campaigns, and applying AI-based diagnostic processes to improve accuracy and efficiency in thyroid cancer diagnosis.

Features of the Global Thyroid Cancer Diagnostic Market

Market Size Estimates: Thyroid cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Thyroid cancer diagnostic market size by product type, test type, end use, and region in terms of value ($B).

Regional Analysis: Thyroid cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, test types, end uses, and regions for the thyroid cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the thyroid cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the thyroid cancer diagnostic market by product type (instruments and consumables & accessories), test type (imaging test, biopsy, blood test, and others), end use (hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Thyroid Cancer Diagnostic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Thyroid Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Thyroid Cancer Diagnostic Market by Product Type
  • 3.3.1: Instruments
  • 3.3.2: Consumables & Accessories
• 3.4: Global Thyroid Cancer Diagnostic Market by Test Type
  • 3.4.1: Imaging Test
  • 3.4.2: Biopsy
  • 3.4.3: Blood Test
  • 3.4.4: Others
• 3.5: Global Thyroid Cancer Diagnostic Market by End Use
  • 3.5.1: Hospital
  • 3.5.2: Associated Labs
  • 3.5.3: Independent Diagnostic Laboratories
  • 3.5.4: Diagnostic Imaging Centers
  • 3.5.5: Cancer Research Institutes
  • 3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Thyroid Cancer Diagnostic Market by Region
• 4.2: North American Thyroid Cancer Diagnostic Market
  • 4.2.1: North American Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.2.2: North American Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.3: European Thyroid Cancer Diagnostic Market
  • 4.3.1: European Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.3.2: European Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.4: APAC Thyroid Cancer Diagnostic Market
  • 4.4.1: APAC Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.4.2: APAC Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.5: ROW Thyroid Cancer Diagnostic Market
  • 4.5.1: ROW Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.5.2: ROW Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Test Type
  • 6.1.3: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by End Use
  • 6.1.4: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Region
• 6.2: Emerging Trends in the Global Thyroid Cancer Diagnostic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Thyroid Cancer Diagnostic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Thyroid Cancer Diagnostic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Hoffmann-La Roche
• 7.3: Thermo Fisher Scientific
• 7.4: Siemens Healthcare
• 7.5: Bio-Rad Laboratories
• 7.6: General Electric
• 7.7: Koninklijke Philips
• 7.8: Toshiba Corporation
• 7.9: Agilent Technologies
• 7.10: Illumina